Drug intelligence / Profile preview

BMS-986447

Development stage: Phase 1
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986447 is an investigational small molecule drug developed by Bristol Myers Squibb. It functions as a selective inhibitor of protein kinase C theta (PKCθ), a member of the protein kinase C family involved in T-cell activation and immune response modulation. The drug has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics following single oral doses in healthy adult participants[3][5][9]. As of June 2025, there are no approved indications or known adverse events reported for this compound.

Targets

PRKCQ (Protein kinase C theta)

Beyond the preview

Go deeper on BMS-986447.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986447.

Explore the full profile